| Project/Area Number |
17K11092
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Anesthesiology
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
Hirate Hiroyuki 名古屋市立大学, 医薬学総合研究院(医学), 研究員 (20363939)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
祖父江 和哉 名古屋市立大学, 医薬学総合研究院(医学), 教授 (90264738)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | ホエイペプチド / 薬物性肝障害 / 周術期管理学 / 栄養療法 |
|---|
| Outline of Final Research Achievements |
With the aging of the population, the number of patients prescribing more drugs due to multiple diseases tends to increase, so that the treatment of drug-induced liver injury in the intensive care unit is expected to become more and more important in the future. In this study, we focused on "whey peptide", which has a hepatoprotective effect, and aimed to investigate the hepatoprotective effect of administration of whey peptide to patients with drug-induced liver injury.
C57BL/6 mice were administered whey peptide-containing liquid diet for 1 week, and then carbon tetrachloride was intraperitoneally administered. Serum AST and ALT in the whey peptide group were significantly decreased 4 hours after administration, suggesting a hepatitis-suppressing effect. In addition, we examined acetaminophen hepatitis model mice and confirmed that serum AST, ALT, and LDH were elevated, but the hepatitis image was not confirmed.
|
| Academic Significance and Societal Importance of the Research Achievements |
今回、明らかにすることはできなかったが、ホエイペプチドの肝保護効果が明らかになれば、今後の栄養学の発展に寄与するとともに、肝障害患者に利用可能な栄養剤の開発につながる可能性がある。
また、ホエイペプチド投与により、薬物性肝障害の改善が期待される。薬物性肝障害以外の肝障害やその他の合併症も予防できる可能性がある。さらに、比較的安価な栄養剤により、合併症の減少や入院期間の短縮ができ、患者の身体的負担の軽減や医療費の削減に貢献できる可能性がある。
|
